Point Biopharma Global Inc. has released new preclinical data from its pan-cancer fibroblast activation protein-α (FAP-α) targeted program, PNT-2004. The preclinical study focused on assessing the potential of the lead candidate in the PNT-2004 clinical program, [177Lu]PNT-6555, in combination with anti-programmed cell death protein 1 (PD-1) immunotherapy.
Umoja Biopharma Inc. and Nanjing Iaso Biotherapeutics Co. Ltd. have entered into a research agreement to evaluate Umoja's ICIL (induced cytotoxic innate lymphocytes) platform with Iaso's best-in-class chimeric antigen receptors (CARs).
Sensei Biotherapeutics Inc. has entered into a sponsored research agreement with Washington University in St. Louis to support development of SNS-101, a conditionally active V-type immunoglobulin domain-containing suppressor of T-cell activation (VISTA)-blocking antibody.
Novaccess Global Inc. has announced the approval of its application with the FDA for orphan drug designation for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. The company’s therapeutic path involves a unique transformational process, which involves the addition of proprietary substances to create a cocktail for more personalized treatment that substantially increases clinical benefits for patients.
The design of genetically modified exosomes that combine multiple targets killed cancer cells and conferred immunity against them. Scientists at the University of Southern California (USC) applied bioengineering techniques to introduce up to four antitumor functions in the same type of extracellular vesicles and destroy EGFR-positive triple-negative breast cancer (TNBC) tumor cells.
Previous research has revealed that some downstream hormones or effectors of the hypothalamic-pituitary (HP) unit, such as glucocorticoids, estrogen and progesterone, are elevated in patients with cancer. It was also shown that these hormones regulate the function of immune cells in the tumor microenvironment, suggesting that the neuroendocrine system and HP unit might modulate tumor immunity. In the current study, researchers from the University of Science and Technology of China aimed to investigate the role of HP unit in tumor immunity.
The interaction of immune checkpoints, such as programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4), with their ligands leads to T-cell deactivation, allowing cancer cells to escape from the immune system.
H-Cyte Inc. has completed its acquisition of Jantibody, a novel cancer immunotherapeutic agent that has demonstrated promising efficacy in controlling ovarian cancer and mesothelioma in preclinical models.
Researchers from CSL Behring LLC have investigated the inhibitory properties of an rFc hexamer, named Fc-muTP-L309C, as a modulator of the classic component pathway activation.